Marksans Pharma Limited (BOM:524404)
India
· Delayed Price · Currency is INR 249.95
-2.00 (-0.79%)
At close: May 28, 2025
Marksans Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Net Income | 3,806 | 3,137 | 2,663 | 1,868 | 2,385 | Upgrade
|
| Depreciation & Amortization | 833.86 | 740.55 | 518.53 | 447.76 | 307.69 | Upgrade
|
| Other Amortization | - | 2.15 | - | - | 5.92 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.33 | -0.94 | 2.64 | - | -0.37 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | 47.9 | Upgrade
|
| Loss (Gain) From Sale of Investments | 33.12 | -43.63 | 108.02 | -56.23 | -16.25 | Upgrade
|
| Provision & Write-off of Bad Debts | 83.28 | 51.57 | 143.61 | 26.32 | 142.83 | Upgrade
|
| Other Operating Activities | -281.96 | -320.71 | 52.89 | -186.4 | 228.9 | Upgrade
|
| Change in Accounts Receivable | -777.9 | -371.67 | -275.18 | -1,039 | -367.44 | Upgrade
|
| Change in Inventory | -1,955 | -1,127 | -448.5 | -178.49 | -1,392 | Upgrade
|
| Change in Accounts Payable | - | - | - | 284.79 | 417.84 | Upgrade
|
| Change in Other Net Operating Assets | 324.83 | 236.48 | -390.97 | -173.98 | 25.75 | Upgrade
|
| Operating Cash Flow | 2,067 | 2,304 | 2,374 | 992.57 | 1,786 | Upgrade
|
| Operating Cash Flow Growth | -10.30% | -2.95% | 139.19% | -44.42% | -23.46% | Upgrade
|
| Capital Expenditures | -1,729 | -2,088 | -536.31 | -463.3 | -464.26 | Upgrade
|
| Sale of Property, Plant & Equipment | 12.49 | 8.54 | 3.77 | 0.34 | 5.2 | Upgrade
|
| Cash Acquisitions | - | - | -266.1 | - | - | Upgrade
|
| Investment in Securities | 269.87 | -259.48 | -1 | -428.55 | - | Upgrade
|
| Other Investing Activities | 956.74 | 930.92 | -1,792 | 47.6 | 10.57 | Upgrade
|
| Investing Cash Flow | -490.09 | -1,408 | -2,592 | -843.91 | -448.49 | Upgrade
|
| Short-Term Debt Issued | - | - | 52.96 | 225.52 | - | Upgrade
|
| Total Debt Issued | - | - | 52.96 | 225.52 | - | Upgrade
|
| Short-Term Debt Repaid | -60.06 | -124.97 | - | - | -1.03 | Upgrade
|
| Long-Term Debt Repaid | -295.65 | -284 | -207.73 | -155.17 | -31.03 | Upgrade
|
| Total Debt Repaid | -355.71 | -408.97 | -207.73 | -155.17 | -32.06 | Upgrade
|
| Net Debt Issued (Repaid) | -355.71 | -408.97 | -154.77 | 70.35 | -32.06 | Upgrade
|
| Repurchase of Common Stock | - | - | -321.14 | - | - | Upgrade
|
| Common Dividends Paid | -271.9 | -226.58 | -101.71 | -105.83 | -40.93 | Upgrade
|
| Dividends Paid | -271.9 | -226.58 | -101.71 | -105.83 | -40.93 | Upgrade
|
| Other Financing Activities | -23.85 | -51.72 | 2,606 | 830.59 | -79.86 | Upgrade
|
| Financing Cash Flow | -651.46 | -687.27 | 1,978 | 795.11 | -152.85 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | - | 0.02 | - | - | Upgrade
|
| Net Cash Flow | 925.09 | 208.4 | 1,760 | 943.77 | 1,185 | Upgrade
|
| Free Cash Flow | 337.45 | 215.69 | 1,838 | 529.27 | 1,322 | Upgrade
|
| Free Cash Flow Growth | 56.45% | -88.26% | 247.24% | -59.95% | -23.79% | Upgrade
|
| Free Cash Flow Margin | 1.29% | 0.99% | 9.92% | 3.55% | 9.60% | Upgrade
|
| Free Cash Flow Per Share | 0.74 | 0.48 | 4.42 | 1.29 | 3.23 | Upgrade
|
| Cash Interest Paid | 23.85 | 51.72 | 60.66 | 80.96 | 79.86 | Upgrade
|
| Cash Income Tax Paid | 1,259 | 1,223 | 630.14 | 728.59 | 485.3 | Upgrade
|
| Levered Free Cash Flow | -735.4 | -510.23 | 661.16 | -227.75 | 528.63 | Upgrade
|
| Unlevered Free Cash Flow | -662.52 | -440.21 | 699.26 | -191.87 | 552.49 | Upgrade
|
| Change in Net Working Capital | 2,550 | 1,496 | 1,081 | 1,514 | 1,229 | Upgrade
|
Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.